51. Scleroderma Disease details / Clinical trials / Drug dev / DR info

0,5 mg Prevenar i.m.   
   Region Skane
      2011   -   NCT02240888   Sweden;
0,5 mg seasonal influenza vaccine i.m.   
   Region Skane
      2011   -   NCT02240888   Sweden;
1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID   
   Inventiva SA
      2017   Phase 2   EUCTR2015-001617-27-SI   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2017   Phase 2   EUCTR2015-001617-27-BG   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-DE   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
   Inventiva SAS
      2016   Phase 2   EUCTR2015-001617-27-NL   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-IT   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-ES   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;
1-22460   
   ao. Univ. Prof. Dr. Elisabeth Aberer
      2006   Phase 4   EUCTR2006-000905-41-AT   Austria;
2 ml of whole blood sample will be collected on EDTA tube   
   Assiut University
      2020   -   NCT04303208   -
2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid   
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt   
   Vicore Pharma AB
      2019   Phase 2   EUCTR2019-003203-35-GB   United Kingdom;
A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R)   
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
ABR-215757   
   Active Biotech AB
      2011   -   EUCTR2011-001667-44-SE   Germany;Sweden;Switzerland;
      2011   -   EUCTR2011-001667-44-DE   Germany;Sweden;Switzerland;
ACE-1334   
   Acceleron Pharma Inc.
      2021   Phase 1/Phase 2   NCT04948554   United States;
ACHIM as solute (10^9 intestinal microbes/ml)   
   Oslo University Hospital
      2020   Phase 2   NCT04300426   Norway;
ACT-064992   
   ACTELION PHARMACEUTICALS LTD.
      2012   -   EUCTR2010-022710-77-IT   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;European Union;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
ACT-293987   
   Actelion Pharmaceuticals Ltd
      2014   -   EUCTR2014-000865-34-GB   Germany;United Kingdom;
      2014   -   EUCTR2014-000865-34-DE   Germany;United Kingdom;
ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE   
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE   
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE   
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE   
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
ADSVF application in the right hand   
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2015   Phase 2   NCT04387825   Mexico;
AIMSPRO   
   Daval International Limited
      2008   Phase 2   EUCTR2007-003122-24-GB   United Kingdom;
AM-01   
   Pharmarama International Limited
      2010   -   EUCTR2009-018194-31-GB   United Kingdom;
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS   
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
AUC of MPA measure   
   Assistance Publique - Hôpitaux de Paris
      2020   -   NCT04244916   France;
AVID200   
   Formation Biologics
      2019   Phase 1   NCT03831438   United States;
Abatacept   
   Dinesh Khanna, MD, MS
      2014   Phase 2   NCT02161406   Canada;United Kingdom;United States;
   Stanford University
      2008   Phase 1/Phase 2   NCT00442611   United States;
   University of Michigan
      2015   Phase 2   EUCTR2014-005323-27-GB   Canada;Italy;United Kingdom;United States;
Abituzumab   
   EMD Serono Research & Development Institute, Inc.
      2016   Phase 2   NCT02745145   Argentina;Australia;Canada;Germany;Israel;Italy;Poland;Spain;Turkey;United Kingdom;United States;
   MERCK KGAA
      2016   Phase 2   EUCTR2015-005023-11-IT   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
Acetaminophen   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
Acetate   
   Kuribayashi Shiko
      2020   -   JPRN-jRCTs031200019   Japan;
Acetylcysteine   
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
Acetylsalicylic acid   
   Federal University of São Paulo
      2018   Phase 4   NCT03558854   Brazil;
Acotiamide   
   Juntendo University School of Medicine
      2018   -   JPRN-UMIN000031901   Japan;
Ad26.COV2.S   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Adempas   
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Adipose tissue harvest   
   University Hospital, Toulouse
      2020   Phase 2   NCT04356755   France;
Administration of rituximab and methylprednisolone   
   University Hospital, Ghent
      2006   Phase 2   NCT00379431   Belgium;
Air filled balloon catheter   
   University of Utah
      2004   Phase 4   NCT00204763   United States;
Albumin   
   Daval International Limited
      2008   Phase 2   NCT00769028   United Kingdom;
Alemtuzumab   
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Alginic acid   
   Khon Kaen University
      2013   Phase 3   NCT01878526   Thailand;
AlloRx   
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05016804   Antigua and Barbuda;
Allogeneic Hematopoietic Stem Cell Transplantation   
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States;
Allogeneic Mesenchymal Stem Cells (AlloMSC)   
   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
      2009   Phase 1/Phase 2   NCT00962923   China;
Alpha-2C AR antagonist   
   Orion Corporation Orion Pharma
      2011   -   EUCTR2010-024005-13-GB   United Kingdom;
Alprostadil   
   NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
      2014   Phase 2   NCT02228850   United States;
Ambrisentan   
   Heidelberg University
      2014   Phase 2   NCT02290613   Germany;
   National Jewish Health
      2012   -   NCT02169752   United States;
   Soumya Chatterjee
      2010   -   NCT01072669   United States;
   Stanford University
      2008   -   NCT00725361   United States;
   Thoraxklinik-Heidelberg gGmbH
      2014   Phase 2   EUCTR2014-001882-28-DE   Germany;
   University of California, Los Angeles
      2009   Phase 4   NCT01051960   United States;
   University of Pennsylvania
      2010   -   NCT01093885   United States;
Amlodipine Gel   
   Pharmarama International Limited
      2010   -   EUCTR2009-018194-31-GB   United Kingdom;
Anaerobically Cultivated Human Intestinal Microbiota   
   Oslo University Hospital
      2018   Phase 1/Phase 2   NCT03444220   Norway;
Anaerobically Cultivated medium   
   Oslo University Hospital
      2018   Phase 1/Phase 2   NCT03444220   Norway;
Anti-CT51 antigen mAb   
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
Anti-Thymocyte Globulin   
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Anti-Thymocyte Globulin, Rabbit   
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Anti-integrin alphaV mAb   
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
Anti-pandemic H1N1 influenza vaccine   
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil;
Anti-thymocyte globulin   
   Fred Hutchinson Cancer Research Center
      2000   Phase 2   NCT00016458   United States;
Asasantin Retard ®   
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom;
Aspirin   
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom;
Assigned Interventions CD19/BCMA CAR T-cells   
   Zhejiang University
      2021   Early Phase 1   NCT05085444   China;
Atorvastatin   
   Robyn T. Domsic, MD, MPH
      2015   Phase 2   NCT02370784   United States;
Autologous ASC   
   CHU de Toulouse
      2020   Phase 2   EUCTR2019-003906-28-FR   France;
   University Hospital, Toulouse
      2020   Phase 2   NCT04356755   France;
Autologous Hematopoietic Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Autologous Regulatory ?-cells   
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2022   Phase 1/Phase 2   NCT05214014   -
Autologous Stem Cells   
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells   
   University Hospital Tuebingen
      2012   Phase 2   NCT01895244   Germany;
Aviptadil   
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
BAY63-2521   
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
BH4   
   VA Office of Research and Development
      2016   Phase 1/Phase 2   NCT02530996   United States;
BIBF 1120   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2018   Phase 3   EUCTR2016-003403-66-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim AB
      2018   Phase 3   EUCTR2016-003403-66-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim B.V
      2018   Phase 3   EUCTR2016-003403-66-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Ellas SA
      2015   Phase 3   EUCTR2015-000392-28-GR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A.
      2015   Phase 3   EUCTR2015-000392-28-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Finland Ky
      2017   Phase 3   EUCTR2015-000392-28-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Fnland Ky
      2018   Phase 3   EUCTR2016-003403-66-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim France
      2015   Phase 3   EUCTR2015-000392-28-FR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2018   Phase 3   EUCTR2016-003403-66-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000392-28-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Norway KS
      2017   Phase 3   EUCTR2015-000392-28-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2015   Phase 3   EUCTR2015-000392-28-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2018   Phase 3   EUCTR2016-003403-66-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim bv
      2017   Phase 3   EUCTR2016-003403-66-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim España, S.A.
      2018   Phase 3   EUCTR2016-003403-66-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim France
      2018   Phase 3   EUCTR2016-003403-66-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim Pharma GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim RCV GmbH&Co KG
      2016   Phase 3   EUCTR2015-000392-28-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm. V
      2018   Phase 3   EUCTR2016-003403-66-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2016   Phase 3   EUCTR2015-000392-28-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
      2018   Phase 3   EUCTR2016-003403-66-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
BMS-986020   
   Bristol-Myers Squibb
      2016   Phase 2   NCT02588625   Canada;France;Poland;United Kingdom;United States;
BNT162b2   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
BOSENTAN MONOHYDRATE   
   University Medical Center Groningen (UMCG)
      2016   -   EUCTR2014-002796-28-NL   Netherlands;
BOTOX® solution   
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03717961   France;
Baricitinib   
   Huashan Hospital, Fudan University
      2021   Phase 0   ChiCTR2100041982   China;
Beam   
   University Hospital, Strasbourg, France
      2015   -   NCT02371005   France;
Belimumab   
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States;
      2012   Phase 2   NCT01670565   United States;
Belumosudil   
   Kadmon Corporation, LLC
      2020   Phase 2   NCT04680975   United States;
Belumosudil (KD025)   
   Kadmon Corporation, LLC
      2019   Phase 2   NCT03919799   United States;
Biopsy   
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
   University Hospital, Bordeaux
      2012   -   NCT02562079   France;
Blood coagulation factor XIII   
   University College London (UCL)
      2015   Phase 2   EUCTR2014-001101-40-GB   United Kingdom;
Blood sample   
   University Hospital, Bordeaux
      2018   -   NCT03575156   France;
Blood samples   
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03508375   France;
   University Hospital, Bordeaux
      2020   -   NCT04265144   France;
      2012   -   NCT02562079   France;
Blood sampling   
   Medical University Innsbruck
      2019   -   NCT04095351   Austria;
Blood test   
   University Hospital, Lille
      2021   -   NCT04746313   France;
Bone marrow transplantation   
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
Bortezomib   
   Northwestern University
      2016   Phase 2   NCT02370693   United States;
Bosentan   
   ACTELION PHARMACEUTICALS ITALIA
      2005   -   EUCTR2004-000632-82-IT   Italy;
      2004   -   EUCTR2004-000631-28-IT   Italy;
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   Phase 3   EUCTR2010-021452-26-FR   France;
   Actelion
      2011   Phase 4   NCT01395732   Netherlands;
      2004   Phase 3   NCT00319696   Austria;Canada;France;Germany;Italy;Switzerland;United Kingdom;United States;
      2004   Phase 2/Phase 3   NCT00319033   Canada;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Sweden;Switzerland;United Kingdom;United States;
      2003   Phase 3   NCT02800993   Canada;United States;
      2003   Phase 3   NCT00077584   Canada;United States;
      2003   Phase 2/Phase 3   NCT00070590   France;Germany;Israel;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States;
   Actelion Pharmaceuticals Japan Ltd.
      2013   Phase 3   JPRN-JapicCTI-132176   -
   Actelion Pharmaceuticals Nederland bv
      2012   -   EUCTR2011-005303-32-NL   Netherlands;
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 2   NCT01241383   France;
   Georgetown University
      2006   Phase 2   NCT00377455   United States;
   Medical University of Graz
      2008   -   NCT00909337   Austria;
   Rikshospitalet University Hospital
      2005   Phase 1/Phase 2   NCT00226889   Norway;
   University College London
      2005   Phase 2   EUCTR2005-000701-61-GB   United Kingdom;
   University Medical Center Groningen
      2015   Phase 4   NCT02480335   Netherlands;
Bosentan (Tracleer)   
   Heinrich-Heine University, Duesseldorf
      2006   Phase 2   NCT00318175   Germany;
Bosentan group   
   Elpen Pharmaceutical Co. Inc.
      2016   -   NCT02798055   Greece;
Bosentan monohydrate   
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom;
Botulinum toxin A   
   Gunma University Hospital
      2014   -   JPRN-UMIN000017617   Japan;
Botulinum toxin type B   
   Gunma University Hospital
      2016   -   JPRN-UMIN000024818   Japan;
Botulinum toxin type B (2500 units / vial)   
   Gunma University
      2016   Phase 2   NCT03007004   Japan;
Botulinum toxin(Botox)   
   University of Texas Southwestern Medical Center
      2020   Early Phase 1   NCT04523506   United States;
Brodalumab   
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   JPRN-JapicCTI-194761   Japan;
      2017   Phase 1   JPRN-JapicCTI-173686   Japan;
Bronchoalveolar lavage (BAL fluid)   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2021   -   NCT05007340   Canada;
Buspirone   
   Laikon General District Hospital, Athens
      2014   Early Phase 1   NCT02363478   Greece;
Busulfan   
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
C-82 Topical Gel,   
   Prism Pharma Co., Ltd.
      2015   Phase 1/Phase 2   NCT02349009   United States;
C21   
   Vicore Pharma AB
      2020   Phase 2   NCT04388176   United Kingdom;
      2019   Phase 2   EUCTR2019-003203-35-GB   United Kingdom;
C225   
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands;
CAM2043   
   Camurus AB
      2020   Phase 2   EUCTR2019-002444-24-GB   United Kingdom;
CAPILLAREMA   
   OSPEDALE MAGGIORE DI MILANO (IRCCS)
      2006   -   EUCTR2006-005230-20-IT   Italy;
CC-4047   
   CELGENE CORPORATION
      2012   Phase 2   EUCTR2010-023047-15-IT   Australia;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-PL   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-ES   Australia;France;Germany;Italy;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
CD34 selected autologous hematopoietic cells   
   University Hospital Tuebingen
      2012   -   EUCTR2011-002434-40-DE   Germany;
CD34+SC   
   University Hospital Tuebingen
      2012   -   EUCTR2011-002434-40-DE   Germany;
COVID-19 Vaccine (ChAdOx1-S [recombinant])   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA Vaccine (nucleoside modified)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine (nucleoside-modified)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 mRNA vaccine Moderna (CX-024414)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
COVID-19 vaccine   
   Paul R Fortin
      2022   Phase 2/Phase 3   NCT05236491   -
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
Calcipotriene   
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
Calcium Channel Blockers   
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Campath   
   Children's Hospital Los Angeles
      2011   -   NCT01639573   United States;
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
Cetuximab   
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands;
Cialis   
   University of Medicine and Dentistry of New Jersey
      2001   Phase 2   NCT00707187   United States;
Clobetasol   
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
Comirnaty   
   Skåne University Hospital, department of rheumatology in Lud and Malmö
      2021   Phase 4   EUCTR2021-000880-63-SE   Sweden;
Companion diagnostic ( CDx)   
   Prometheus Biosciences, Inc.
      2022   Phase 2   NCT05270668   United States;
Cuprimine (penicillamine)   
   Merck Sharp & Dohme Corp.
      2010   -   NCT01374282   -
Currently available therapy in the community   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   -   NCT00860548   United States;
Cutaneous iontophoresis of treprostinil   
   University Hospital, Grenoble
      2012   Phase 1/Phase 2   NCT01554540   France;
Cyclophosphamide   
   Akashi Koichi
      2019   Phase 2   JPRN-jRCTc071190041   Japan;
   Assistance Publique - Hôpitaux de Paris
      2013   Phase 3   NCT01570764   France;
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States;
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
      2000   Phase 2   NCT00016458   United States;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Kyushu University
      2010   Phase 2   JPRN-UMIN000031940   Japan;
   Michael Roth
      2009   Phase 2   NCT00883129   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2/Phase 3   NCT00114530   Canada;United States;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom;
   The University of Texas Health Science Center, Houston
      1999   Phase 3   NCT00004563   -
   University of Manchester
      2010   -   NCT02339441   -
Cyclophosphamide Injection 1g   
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
DI-17E6   
   Merck KGaA
      2016   Phase 2   EUCTR2015-005023-11-PL   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-GB   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-005023-11-ES   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
DIGNA P144 CREAM   
   ISDIN
      2007   Phase 2   EUCTR2007-002015-38-GB   Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002015-38-HU   Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002015-38-ES   Germany;Hungary;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002015-38-DE   Germany;Hungary;Italy;Spain;United Kingdom;
DIGNA P144 cream   
   ISDIN
      2008   -   EUCTR2008-001265-28-HU   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-GB   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-ES   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-DE   Germany;Hungary;Italy;Spain;United Kingdom;
Dabigatran etexilate   
   Medical University of South Carolina
      2016   Phase 1   NCT02426229   United States;
Dasatinib   
   Bristol-Myers Squibb
      2009   Phase 1/Phase 2   NCT00764309   United States;
Depletion of CD3/CD19 in an autologous stem cell transplant   
   Stephan Grupp MD PhD
      2021   Phase 2   NCT05029336   United States;
Depot leuprolide acetate   
   Joseph Mccune
      2011   Phase 3   NCT01257802   United States;
Dersimelagon   
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2021   Phase 2   EUCTR2020-000134-17-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000134-17-GB   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 2   EUCTR2020-000134-17-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
Diltiazem Gel   
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of;
Dimethyl Fumarate (DMF)   
   Robert Lafyatis
      2016   Phase 1   NCT02981082   United States;
Diphenhydramine   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
Dipyridamole   
   Royal National Hospital for Rheumatic Disease
      2010   Phase 2   EUCTR2009-013468-37-GB   United Kingdom;
Divalproex sodium   
   Yale University
      2014   Phase 1/Phase 2   NCT02166229   United States;
Domperidone   
   Khon Kaen University
      2013   Phase 3   NCT01878526   Thailand;
Double-Blind Rituximab   
   Tokyo University
      2017   Phase 2/Phase 3   NCT04274257   Japan;
Drug treatment   
   Federal University of São Paulo
      2010   Phase 3   NCT01586663   Brazil;
Dupilumab   
   University of Cologne
      2019   Phase 2   EUCTR2019-002036-90-DE   Germany;
Dupilumab 300Mg Solution for Injection   
   University of Cologne
      2020   Phase 2   NCT04200755   Germany;
EMA/CHMP/212874/2015   
   University Medial Center Groningen
      2018   Phase 4   EUCTR2018-001719-65-NL   Netherlands;
EMD 525797   
   MERCK KGAA
      2016   Phase 2   EUCTR2015-005023-11-IT   Argentina;Australia;Canada;France;Israel;Italy;Poland;Singapore;Spain;Turkey;United Kingdom;United States;
ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy;
ENDOPROST 0,05MG/0,5ML 1F   
   ITALFARMACO
      2005   -   EUCTR2004-002712-28-IT   Italy;
ENDOPROST 50*INFUS 1F 0,050MG/   
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
EX VIVO CULTURED HUMAN MESENCHYMAL STEM CELLS   
   University Medical Center Utrecht
      2016   Phase 2   EUCTR2015-000168-32-NL   Netherlands;
Endoprost   
   Azienda ospedaliera universitaria Ospedali Riuniti
      2014   Phase 2   EUCTR2013-004596-12-IT   Italy;
Endothelin receptor blocker   
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Erbitux   
   VU University Medical Centre
      2006   -   EUCTR2006-002081-19-NL   Netherlands;
Esbriet   
   InterMune Inc.
      2013   -   EUCTR2013-001353-28-IT   Canada;Italy;United States;
Ethanol   
   Indonesia University
      2016   -   NCT03141125   Indonesia;
FCR001   
   Talaris Therapeutics Inc.
      2021   Phase 1/Phase 2   NCT05098145   United States;
FCX-013   
   Castle Creek Biosciences, LLC.
      2019   Phase 1/Phase 2   NCT03740724   United States;
FT011   
   Certa Therapeutics
      2021   Phase 2   NCT04647890   Australia;
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
Fasudil   
   Johns Hopkins University
      2007   Phase 3   NCT00498615   United States;
Fibrogammin® 1250   
   University College London (UCL)
      2015   Phase 2   EUCTR2014-001101-40-GB   United Kingdom;
Fibrogammin®P, coagulation factor XIII concentrate (Human)   
   University College, London
      2015   Phase 2   NCT02551042   United Kingdom;
Filgrastim   
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
   Northwestern University
      2011   Phase 3   NCT01445821   United States;
Fludarabine   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
Fludarabine phosphate   
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
Fractional carbon dioxide laser   
   Cairo University
      2013   -   NCT02002897   Egypt;
Fresolimumab   
   Boston University
      2011   Phase 1   NCT01284322   United States;
From August 2020 'no additional treatment'   
   Prof. Ariane herrick
      2017   Phase 2   NCT03708718   United Kingdom;
G-CSF   
   Akashi Koichi
      2019   Phase 2   JPRN-jRCTc071190041   Japan;
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
   Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
      2007   Phase 1,2   JPRN-UMIN000000589   Japan;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
G451990   
   GALAPAGOS NV
      2019   Phase 2   EUCTR2019-001279-34-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
   Galapagos NV
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-ES   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-BE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
GLIVEC   
   AZIENDA OSPEDALIERA S. CARLO
      2007   -   EUCTR2007-001508-19-IT   Italy;
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2007   -   EUCTR2007-005322-68-IT   Italy;
   NOVARTIS FARMA
      2008   -   EUCTR2007-004669-17-IT   Italy;United Kingdom;
GLPG1690   
   GALAPAGOS NV
      2019   Phase 2   EUCTR2019-001279-34-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-IT   Belgium;Germany;Italy;Spain;United Kingdom;United States;
   Galapagos NV
      2019   Phase 2   NCT03976648   Belgium;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   NCT03798366   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-ES   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001279-34-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-DE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001817-33-BE   Belgium;Germany;Italy;Spain;United Kingdom;United States;
GM-CSF   
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
GS-248   
   Gesynta Pharma AB
      2020   Phase 2   NCT04744207   Belgium;Netherlands;Poland;United Kingdom;
      2020   Phase 2   EUCTR2020-002081-13-PL   Netherlands;Poland;United Kingdom;
      2020   Phase 2   EUCTR2020-002081-13-NL   Netherlands;Poland;United Kingdom;
      2020   Phase 2   EUCTR2020-002081-13-GB   United Kingdom;
      2019   Phase 1   NCT04036227   Sweden;
GSK2330811   
   GlaxoSmithKline
      2017   Phase 2   NCT03041025   Canada;Netherlands;United Kingdom;United States;
      2015   Phase 1   NCT02386436   United Kingdom;
GSK2330811 Solution for Injection, 100mg/ml   
   GlaxoSmithKline Research & Development Ltd
      2018   Phase 2   EUCTR2016-003417-95-NL   Canada;Netherlands;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003417-95-GB   Netherlands;United Kingdom;United States;
Glivec   
   ErasmusMC
      2007   -   EUCTR2006-007091-15-NL   Netherlands;
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom;
Glivec 100 mg Filmtabletten   
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom;
Glycyrrhizin   
   Sumida Hayakazu
      2020   -   JPRN-jRCTs031180366   Japan;
Gran   
   Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
      2007   Phase 1,2   JPRN-UMIN000000589   Japan;
Guselkumab   
   Numaguchi Hirotaka
      2021   Phase 2   JPRN-jRCT2051200133   Japan;
Guselkumab Dose 1   
   Janssen Pharmaceutical K.K.
      2021   Phase 2   NCT04683029   Japan;
Guselkumab Dose 2   
   Janssen Pharmaceutical K.K.
      2021   Phase 2   NCT04683029   Japan;
HIDONAC*EV 1FL 5G 25ML   
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
HZN-825   
   HORIZON THERAPEUTICS IRELAND DAC
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-IT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2020-005764-62-PL   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 2   EUCTR2020-005764-62-NL   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-PT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-005764-62-ES   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005764-62-GR   Argentina;Austria;Belgium;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005764-62-DE   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005764-62-AT   Argentina;Austria;Belgium;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
HZN-825 BID   
   Horizon Therapeutics Ireland DAC
      2021   Phase 2   NCT04781543   Argentina;France;Greece;Korea, Republic of;Portugal;United States;
HZN-825 QD   
   Horizon Therapeutics Ireland DAC
      2021   Phase 2   NCT04781543   Argentina;France;Greece;Korea, Republic of;Portugal;United States;
Hematopoietic stem cell transplantation   
   Richard Burt, MD
      2005   Phase 1   NCT00282425   United States;
High-dose intravenous immunoglobulin (Venoglobulin-IH)   
   Benesis Corporation
      2006   Phase 3   NCT00348296   Japan;
Hizentra   
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody   
   Genzyme, a Sanofi Company
      2002   Phase 1/Phase 2   NCT00043706   United States;
Human normal immunoglobulin for intravenous (IV) administration   
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
Human normal immunoglobulin for intravenous administration   
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Human normal immunoglobulin for subcutaneous administration   
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Hyaluronidase injected intradermally   
   Brigham and Women's Hospital
      2020   Early Phase 1   NCT04656704   -
Hyperimmune caprine serum   
   Daval International Limited
      2008   Phase 2   NCT00769028   United Kingdom;
Hyperoxia   
   University of British Columbia
      2022   -   NCT03800017   -
ILOPROST SALE DI TROMETAMOLO   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy;
ILOPROST TROMETAMOL   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2017   Phase 4   EUCTR2016-002984-32-IT   Italy;
IMATINIB MESILATO   
   NOVARTIS FARMA
      2008   -   EUCTR2007-004669-17-IT   Italy;United Kingdom;
IMMUNOGLOBULINA UMANA NORMALE   
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
INCB039110   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 2   EUCTR2019-003430-16-FR   France;
INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS   
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 1/Phase 2   NCT02213705   France;
IS (B cell depletion therapy)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MMF or MPA)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MTX)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IV Cyclophosphamide   
   Johns Hopkins University
      2001   Phase 3   NCT00501995   United States;
IVA337   
   Inventiva Pharma
      2015   Phase 2   NCT02503644   Bulgaria;France;Germany;Italy;Netherlands;Poland;Slovenia;Spain;Switzerland;United Kingdom;
   Inventiva SA
      2017   Phase 2   EUCTR2015-001617-27-SI   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2017   Phase 2   EUCTR2015-001617-27-BG   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-GB   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-DE   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
   Inventiva SAS
      2016   Phase 2   EUCTR2015-001617-27-NL   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-IT   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;United Kingdom;
      2015   Phase 2   EUCTR2015-001617-27-ES   Bulgaria;Germany;Italy;Netherlands;Slovenia;Spain;Switzerland;
IVIg   
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
Idrossiclorochina solfato   
   UMBERTO I - POLICLINICO DI ROMA
      2022   Phase 3   EUCTR2021-000230-33-IT   Italy;
IgPro10   
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring
      2019   Phase 2   NCT04138485   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   NCT04137224   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
IgPro20   
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring
      2019   Phase 2   NCT04137224   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
Iguratimod   
   RenJi Hospital
      2021   -   NCT04515706   -
Ilomedin   
   ao. Univ. Prof. Dr. Elisabeth Aberer
      2006   Phase 4   EUCTR2006-000905-41-AT   Austria;
Iloprost   
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2006   -   EUCTR2006-003957-25-IT   Italy;
   National Center for Research Resources (NCRR)
      1995   Phase 3   NCT00004786   -
Iloprost Injection, for intravenous use   
   Eicos Sciences, Inc.
      2019   Phase 3   NCT04040322   United States;
      2019   Phase 2   NCT03867097   United States;
Iloprost low dose   
   Charite University, Berlin, Germany
      1997   Phase 2   NCT00622687   Germany;
Iloprost therapy up to 2 ng/kg x min   
   Charite University, Berlin, Germany
      1997   Phase 2   NCT00622687   Germany;
Iloprost trometamol   
   ITALFARMACO
      2005   -   EUCTR2004-002712-28-IT   Italy;
Imatinib   
   AZIENDA OSPEDALIERA S. CARLO
      2007   -   EUCTR2007-001508-19-IT   Italy;
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2007   -   EUCTR2007-005322-68-IT   Italy;
   Azienda Ospedaliera Universitaria Policlinico
      2009   Phase 2   NCT00573326   Italy;
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom;
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom;
   University of California, Los Angeles
      2007   Phase 1/Phase 2   NCT00512902   United States;
Imatinib Mesylate   
   Hospital for Special Surgery, New York
      2007   Phase 2   NCT00555581   United States;
Imatinib mesylate   
   Lawson Health Research Institute
      2008   Phase 2   NCT01545427   Canada;
   Lee, Stephanie
      2011   Phase 2   NCT01309997   United States;
   Stanford University
      2007   Phase 1/Phase 2   NCT00506831   United States;
   University Hospital, Bordeaux
      2007   Phase 2   NCT00479934   France;
Imiquimod cream   
   The Hospital for Sick Children
      2005   Phase 3   NCT00147771   Canada;
Immunoglobulina Normale Umana per somministrazione endovenosa   
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
Immunoglobulina Normale Umana per somministrazione sottocutanea   
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
Immunoglobulina normale umana per somministrazione endovenosa   
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
Imnovid 1 mg hard capsules   
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-GB   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-DE   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Inebilizumab   
   Kondou Kazuoki
      2022   Phase 3   JPRN-jRCT2031210521   Japan;
   Mitsubishi Tanabe Pharma Corporation
      2022   Phase 3   NCT05198557   Japan;
Influenza vaccine   
   Tel-Aviv Sourasky Medical Center
      2009   Phase 4   NCT01002508   Israel;
Injection of autologous stromal vascular fraction   
   The Catholic University of Korea
      2016   -   NCT02975960   Korea, Republic of;
Intravenous immunoglobulin   
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Iontophoresis of treprostinil   
   University Hospital, Grenoble
      2017   Phase 1/Phase 2   NCT03120533   France;
Itacitinib   
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT04789850   France;
Ixazomib   
   W. Leroy Griffing
      2021   Phase 2   NCT04837131   United States;
JBT-101   
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-PL   Australia;Austria;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 2   NCT02465437   United States;
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-NL   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-000372-29-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
KHK4827   
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   NCT03957681   Japan;
      2019   Phase 3   JPRN-JapicCTI-194761   Japan;
      2017   Phase 1   NCT04368403   Japan;
      2017   Phase 1   JPRN-JapicCTI-173686   Japan;
Lactobacillus   
   University of Michigan
      2012   Phase 4   NCT01497743   United States;
Lenabasum   
   Corbus Pharmaceuticals Inc.
      2017   Phase 3   NCT03398837   Australia;Canada;Germany;Israel;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Lenabasum 20 mg Powder in Capsule   
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Lenabasum 5 mg Powder in Capsule   
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Lenabasum 5mg Powder in Capsule   
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Leukapheresis   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
Leukopheresis   
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
Lidocaine without vessel constrictor   
   Federal University of São Paulo
      2004   Phase 2/Phase 3   NCT00740285   Brazil;
Lipitor   
   Salford Royal Hospitals NHS Trust
      2008   Phase 4   EUCTR2005-003775-21-GB   United Kingdom;
Liposomal bupivacaine   
   Jose Soberon, MD
      2014   Phase 2/Phase 3   NCT02374320   United States;
MABp1 (Bermekimab)   
   Hellenic Institute for the Study of Sepsis
      2019   Phase 2   NCT04045743   Greece;
MEDI-546   
   MedImmune LLC
      2009   Phase 1   NCT00930683   United States;
MEDI-551   
   MedImmune LLC
      2010   Phase 1   NCT00946699   Canada;United Kingdom;United States;
METHYLPREDNISOLONE SODIUM SUCCINATE   
   Radboudumc
      2019   Phase 4   EUCTR2015-004613-24-BE   Belgium;Netherlands;
      2016   Phase 4   EUCTR2015-004613-24-NL   Netherlands;
METOCLOPRAMIDE ACCORD - 10 MG COMPRESSE 28 COMPRESSE IN BLISTER PVC/PVDC/AL   
   MEDAC GMBH
      2016   Phase 3   EUCTR2015-002586-39-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
MHSCT   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2/Phase 3   NCT00114530   Canada;United States;
MMF   
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States;
MPA   
   Region Skane
      2018   -   NCT03678987   Sweden;
MQX-503   
   MediQuest Therapeutics
      2006   Phase 2   NCT00378521   United States;
   MediQuest Therapeutics, Inc.
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom;
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom;
MSC   
   University Medical Center Utrecht
      2016   Phase 2   EUCTR2015-000168-32-NL   Netherlands;
MT-7117   
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 2   EUCTR2020-000134-17-IT   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2021   Phase 2   EUCTR2020-000134-17-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000134-17-GB   Belgium;Canada;Germany;Italy;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America, Inc.
      2021   Phase 2   NCT04440592   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 2   EUCTR2020-000134-17-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
MabThera   
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
   University Hospital Gent
      2006   -   EUCTR2006-003836-31-BE   Belgium;
Macitentan   
   ACTELION PHARMACEUTICALS LTD.
      2012   -   EUCTR2010-022710-77-IT   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;European Union;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
   Actelion
      2011   Phase 3   NCT01474122   Argentina;Belgium;China;Colombia;Germany;Greece;Ireland;Israel;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01474109   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
   Actelion Pharmaceuticals Ltd
      2014   -   EUCTR2010-022710-77-CZ   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United Kingdom;
      2012   Phase 3   EUCTR2010-022969-95-BE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-PT   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-PL   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-NL   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022969-95-GR   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-022710-77-PL   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2012   -   EUCTR2010-022710-77-FI   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   Phase 3   EUCTR2010-022969-95-GB   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022969-95-IE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022969-95-ES   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022969-95-DE   Argentina;Belgium;Colombia;Germany;Greece;Ireland;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-022710-77-HU   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   -   EUCTR2010-022710-77-DK   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   -   EUCTR2010-022710-77-DE   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
      2011   -   EUCTR2010-022710-77-BG   Australia;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Italy;Poland;Russian Federation;Ukraine;United States;
Manual toothbrush and water flosser (Philips Sonicare AirFloss)   
   University Hospital, Strasbourg, France
      2021   -   NCT04627857   France;
Measurment with Aspirational Medical Device   
   Oliver Distler
      2018   -   NCT03644225   Switzerland;
Measurment with Cutometer MPA 580   
   Oliver Distler
      2018   -   NCT03644225   Switzerland;
Mesenchymal Stem Cells from Wharton ´s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ´s jelly   
   Universidad de la Sabana
      2022   -   NCT04432545   Colombia;
Mesna   
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Methotrexate   
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2020   Phase 0   ChiCTR2000031572   China;
   University of California, Los Angeles
      2002   Phase 1/Phase 2   NCT00241189   United States;
   University of Manchester
      2010   -   NCT02339441   -
Methoxsalen   
   Lawson Health Research Institute
      2022   Phase 2   NCT04986605   Canada;
Methylprednisolon   
   Radboudumc
      2019   Phase 4   EUCTR2015-004613-24-BE   Belgium;Netherlands;
      2016   Phase 4   EUCTR2015-004613-24-NL   Netherlands;
Methylprednisolone   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
   Radboud University
      2017   Early Phase 1   NCT03059979   Netherlands;
Methylprednisolone acetate   
   Assiut University
      2018   -   NCT03742466   Egypt;
Metronidazole   
   Coordinación de Investigación en Salud, Mexico
      2015   Phase 4   NCT03692299   Mexico;
Microgynon   
   Boehringer Ingelheim
      2018   Phase 1   NCT03675581   Belgium;France;Germany;Netherlands;Portugal;Spain;
Mizoribine   
   Faculty of Life Sciences, Kumamoto University
      2010   -   JPRN-UMIN000004162   Japan;
Moderna mRNA-1273   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Mycophenolate Mofetil (MMF)   
   Michael Roth
      2017   Phase 2   NCT03221257   United States;
Mycophenolate mofetil   
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Michael Roth
      2009   Phase 2   NCT00883129   United States;
   Northwestern University
      2016   Phase 2   NCT02370693   United States;
   Postgraduate Institute of Medical Education and Research
      2016   Phase 3   NCT02896205   India;
   UMC Utrecht
      2020   Phase 4   EUCTR2019-004718-32-NL   Netherlands;
   University of California, San Francisco
      2006   -   NCT00333437   United States;
   University of Manchester
      2010   -   NCT02339441   -
Mycophenolic acid   
   Region Skane
      2018   -   NCT03678987   Sweden;
N-acetylcysteine (NAC)   
   Università Politecnica delle Marche
      2007   Phase 2/Phase 3   NCT00428883   Italy;
NON PROPIETRY, THEREFORE N/A   
   Salford Royal Hospitals Trust
      2007   Phase 2   EUCTR2004-002799-41-GB   United Kingdom;
Nemolizumab   
   Maruho Co., Ltd.
      2022   Phase 2   NCT05214794   Japan;
   Nishiura Tomoyuki
      2021   Phase 2   JPRN-jRCT2031210481   Japan;
Neovasculgen   
   Human Stem Cell Institute, Russia
      2015   Phase 1/Phase 2   NCT02356809   Russian Federation;
Neupogen   
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Nilotinib (Tasigna)   
   Hospital for Special Surgery, New York
      2010   Phase 2   NCT01166139   United States;
Nintedanib   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim
      2020   -   NCT04325217   Japan;
      2018   Phase 1   NCT03675581   Belgium;France;Germany;Netherlands;Portugal;Spain;
      2017   Phase 3   NCT03313180   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   NCT02597933   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Nitroglycerin   
   MediQuest Therapeutics
      2007   Phase 3   NCT00577304   United States;
Nitroglycerin Ointment   
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of;
Nitroglycerine gel   
   MediQuest Therapeutics, Inc.
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom;
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom;
Nitroglycerine in Propylene Glycol, USP   
   MediQuest Therapeutics, Inc.
      2006   Phase 3   EUCTR2005-004979-37-GB   Sweden;United Kingdom;
      2006   -   EUCTR2005-004979-37-SE   Sweden;United Kingdom;
Nivolumab   
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States;
Non applicabile   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2016   Phase 2   EUCTR2016-001028-80-IT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
None yet   
   Certa Therapeutics Pty Ltd
      2021   Phase 2   EUCTR2020-005116-21-PL   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
      2021   Phase 2   EUCTR2020-005116-21-ES   Australia;Netherlands;Poland;Russian Federation;Spain;Ukraine;
Nonmyeloablative allogeneic hematopoietic stem cell transplantation   
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
ORM-12471   
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01315899   United Kingdom;
ORM-12741   
   Orion Corporation Orion Pharma
      2011   -   EUCTR2010-024005-13-GB   United Kingdom;
Ofev   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2018   Phase 3   EUCTR2016-003403-66-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim AB
      2018   Phase 3   EUCTR2016-003403-66-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim B.V
      2018   Phase 3   EUCTR2016-003403-66-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Ellas SA
      2015   Phase 3   EUCTR2015-000392-28-GR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A.
      2015   Phase 3   EUCTR2015-000392-28-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Finland Ky
      2017   Phase 3   EUCTR2015-000392-28-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Fnland Ky
      2018   Phase 3   EUCTR2016-003403-66-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim France
      2015   Phase 3   EUCTR2015-000392-28-FR   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2018   Phase 3   EUCTR2016-003403-66-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000392-28-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Norway KS
      2017   Phase 3   EUCTR2015-000392-28-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2015   Phase 3   EUCTR2015-000392-28-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2018   Phase 3   EUCTR2016-003403-66-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-000392-28-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer Ingelheim bv
      2017   Phase 3   EUCTR2016-003403-66-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim España, S.A.
      2018   Phase 3   EUCTR2016-003403-66-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim France
      2018   Phase 3   EUCTR2016-003403-66-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim Pharma GmbH & Co. KG
      2018   Phase 3   EUCTR2016-003403-66-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Boehringer-Ingelheim RCV GmbH&Co KG
      2016   Phase 3   EUCTR2015-000392-28-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm. V
      2018   Phase 3   EUCTR2016-003403-66-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000392-28-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2016   Phase 3   EUCTR2015-000392-28-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
      2018   Phase 3   EUCTR2016-003403-66-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Omeprazole   
   Khon Kaen University
      2013   Phase 1   NCT03561233   -
Onabotulinumtoxin A   
   Johns Hopkins University
      2015   Phase 3   NCT02165111   United States;
Ophthalmic Emulsion   
   Allergan
      2001   Phase 3   NCT00025818   United States;
Opsumit 10 Mg Tablet   
   Franz Rischard, DO
      2018   Phase 2/Phase 3   NCT03726398   United States;
Oral Ifetroban   
   Cumberland Pharmaceuticals
      2017   Phase 2   NCT02682511   India;United States;
Oral bovine type I collagen   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2000   Phase 2   NCT00005675   United States;
Oral treprostinil   
   Stanford University
      2016   Phase 2   NCT02663895   United States;
Order of two elements of surgical procedure   
   Duke University
      2017   Phase 4   NCT03155464   -
Other vasodilator   
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Ozone   
   Assiut University
      2018   -   NCT03742466   Egypt;
   Pamukkale University
      2021   -   NCT04826419   Turkey;
P144   
   ISDIN
      2007   Phase 2   NCT00574613   Germany;Hungary;Italy;Poland;Spain;United Kingdom;
   ISDIN S.A.
      2009   -   EUCTR2007-002015-38-IT   Germany;Hungary;Italy;Spain;United Kingdom;
P144 Cytokine Inhibitor   
   ISDIN
      2008   -   EUCTR2008-001265-28-DE   Germany;Hungary;Italy;Spain;United Kingdom;
P144 Cytokines Inhibitors   
   ISDIN
      2008   -   EUCTR2008-001265-28-HU   Germany;Hungary;Italy;Spain;United Kingdom;
   ISDIN S.A.
      2010   -   EUCTR2008-001265-28-IT   Germany;Hungary;Italy;Spain;United Kingdom;
P144 DIGNA CREAM   
   ISDIN
      2007   Phase 2   EUCTR2007-002015-38-GB   Germany;Hungary;Italy;Spain;United Kingdom;
P144 cream   
   ISDIN
      2008   Phase 2   NCT00781053   Germany;Hungary;Italy;Poland;Spain;United Kingdom;
P144. Cytokines Inhibitors   
   ISDIN
      2008   -   EUCTR2008-001265-28-GB   Germany;Hungary;Italy;Spain;United Kingdom;
      2008   -   EUCTR2008-001265-28-ES   Germany;Hungary;Italy;Spain;United Kingdom;
   ISDIN S.A.
      2010   -   EUCTR2008-001265-28-IT   Germany;Hungary;Italy;Spain;United Kingdom;
PLACENTEX ® Polydeoxyribonucleotide   
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml   
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿   
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
POLYDEOXYRIBONUCLEOTIDES   
   MASTELLI SRL
      2016   Phase 4   EUCTR2015-005100-28-IT   Italy;
PR1   
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany;
PRA023 IV   
   Prometheus Biosciences, Inc.
      2022   Phase 2   NCT05270668   United States;
PRIVIGEN - 100 MG/ML - SOLUZIONE PER INFUSIONE USO ENDOVENOSO FLACONCINO(VETRO) 1 FLACONCINO DA 100 ML   
   CSL BEHRING GMBH
      2020   Phase 2   EUCTR2019-000906-31-IT   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
PRUCALOPRIDE SUCCINATE   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2013   -   EUCTR2012-005348-92-IT   Italy;
Paquinimod   
   Active Biotech AB
      2011   Phase 2   NCT01487551   Germany;Sweden;Switzerland;
      2011   -   EUCTR2011-001667-44-SE   Germany;Sweden;Switzerland;
      2011   -   EUCTR2011-001667-44-DE   Germany;Sweden;Switzerland;
Part B Open-Label Extension   
   Corbus Pharmaceuticals Inc.
      2015   Phase 2   NCT02465437   United States;
Patients will be randomized to receive EHP-101   
   Emerald Health Pharmaceuticals
      2020   Phase 2   NCT04166552   Australia;New Zealand;United States;
Peripheral Blood Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Peripheral Blood Stem Cells   
   Northwestern University
      2011   Phase 3   NCT01445821   United States;
Peripheral blood stem cell transplantation   
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
Phosphodiesterase Inhibitors   
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Physiological saline   
   Gunma University
      2016   Phase 2   NCT03007004   Japan;
Pirfenidone   
   Beijing Continent Pharmaceutical Co, Ltd.
      2018   Phase 3   NCT03856853   China;
   Genentech, Inc.
      2013   Phase 2   NCT01933334   Canada;Italy;United States;
   RenJi Hospital
      2017   Phase 2/Phase 3   NCT03068234   China;
Pirfenidone (PFD)   
   Michael Roth
      2017   Phase 2   NCT03221257   United States;
Placebo   
   Chugai Pharmaceutical Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-152963   Japan, North America, Europe, 25 countries including Japan, US, UK, Germany etc.;
   Kyowa Kirin Co., Ltd.
      2019   Phase 3   JPRN-JapicCTI-194761   Japan;
Platelet Gel   
   Università Politecnica delle Marche
      2007   Phase 2/Phase 3   NCT00463125   Italy;
Plerixafor   
   Fred Hutchinson Cancer Research Center
      2011   Phase 2   NCT01413100   Canada;United States;
Polydeoxyribonucleotides   
   Mastelli S.r.l
      2016   Phase 4   NCT03388255   Italy;
Pomalidomida   
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-ES   Australia;France;Germany;Italy;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Pomalidomide   
   CELGENE CORPORATION
      2012   Phase 2   EUCTR2010-023047-15-IT   Australia;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Celgene Corporation
      2012   Phase 2   EUCTR2010-023047-15-PL   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-GB   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   EUCTR2010-023047-15-DE   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Pomalidomide (CC-4047)   
   Celgene
      2012   Phase 2   NCT01559129   Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Prednisolon   
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolona   
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolone   
   Prof. Ariane herrick
      2017   Phase 2   NCT03708718   United Kingdom;
Prednisolone 5mg Gastro-resistant Tablets   
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolone and taper   
   Khon Kaen University
      2018   Phase 2   NCT03607071   Thailand;
Prednisoloni   
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisolonum   
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednisone   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
Prednizolon   
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Prednizolonas   
   Research Governance and Integrity, University of Manchester
      2017   Phase 2   EUCTR2016-002651-25-GB   United Kingdom;
Privigen   
   CSL BEHRING GMBH
      2019   Phase 2   EUCTR2018-003149-41-IT   Australia;France;Germany;Italy;Poland;United Kingdom;
   CSL Behring GmbH
      2020   Phase 2   EUCTR2019-000906-31-PL   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-GB   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-DE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-000906-31-BE   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-FR   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000906-31-ES   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Mexico;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003149-41-GB   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-FR   Australia;France;Germany;Italy;Poland;United Kingdom;
      2019   Phase 2   EUCTR2018-003149-41-DE   Australia;France;Germany;Italy;Poland;United Kingdom;
   Georgetown University
      2013   -   NCT01785056   United States;
Prostanoids   
   Seoul National University Hospital
      2015   -   NCT02642146   Korea, Republic of;
Pyrophosphate   
   Szeged University
      2021   -   NCT04966416   -
QAX576   
   Novartis Pharmaceuticals
      2007   Phase 2   NCT00581997   United States;
Quality-of-life assessment   
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
RATG   
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
      2011   Phase 3   NCT01445821   United States;
RESOLOR*28CPR RIV   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2013   -   EUCTR2012-005348-92-IT   Italy;
RO487-7533/F10-04   
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 3   EUCTR2015-000424-28-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-000424-28-IE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000424-28-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE   
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 3   EUCTR2015-000424-28-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
Rabeprazole   
   Faculty of Medicine,Institute of Medical, Pharmaceutical and Health Sciences,Kanazawa University
      2005   -   JPRN-UMIN000020701   Japan;
Rapamycin   
   University of California, Los Angeles
      2002   Phase 1/Phase 2   NCT00241189   United States;
RbATG   
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Recombinant humanized anti-human monoclonal antibody directed against the IL-6R   
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Reduced Intensity Allogeneic Transplant   
   New York Medical College
      2007   Phase 1   NCT00684255   United States;
Reduced intensity allogeneic hematopoietic stem cell transplantation   
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
Relaxin   
   National Center for Research Resources (NCRR)
      1991   Phase 2   NCT00004380   -
   University of Medicine and Dentistry of New Jersey
      1998   Phase 3   NCT00704665   -
Resunab, ajulemic acid, anabasum   
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 3   EUCTR2017-000372-29-IT   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-PL   Australia;Austria;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-000372-29-NL   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-ES   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-000372-29-DE   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Corbus pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-000372-29-GB   Australia;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Rilonacept   
   Boston University
      2011   Phase 1/Phase 2   NCT01538719   United States;
Ringer lactate   
   Assistance Publique Hopitaux De Marseille
      2017   Phase 2   NCT02866552   France;
      2015   Phase 2   NCT02558543   France;
Riocigu   
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Riociguat   
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2014-001353-16-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Dinesh Khanna, MD, MS
      2016   Phase 2   NCT02915835   United States;
Riociguat (Adempas, BAY63-2521)   
   Bayer
      2015   Phase 2   NCT02283762   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Riociguat coated tablet   
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001353-16-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 2   EUCTR2014-001353-16-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001353-16-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States;
Riociguat coated tablet 2.5 m   
   Bayer AG
      2015   Phase 2   EUCTR2014-001353-16-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;New Zealand;Spain;Switzerland;Turkey;United Kingdom;United States;
Rituximab   
   Assistance Publique - Hôpitaux de Paris
      2013   Phase 2/Phase 3   NCT01748084   France;
   Department of Dermatology, University of Tokyo
      2012   -   JPRN-UMIN000007702   Japan;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Hospital for Special Surgery, New York
      2019   Phase 2   NCT03844061   United States;
   LUMC
      2009   -   EUCTR2008-007180-16-NL   Netherlands;
   Lee, Stephanie
      2011   Phase 2   NCT01309997   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2011   Phase 2   NCT01086540   United States;
   Northwestern University
      2018   Phase 2/Phase 3   NCT03593902   United States;
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
   Royal Brompton & Harefield NHS Foundation Trust
      2014   Phase 2/Phase 3   NCT01862926   United Kingdom;
   Royal Brompton and Harefield NHS Foundation Trust
      2013   -   EUCTR2012-003633-42-GB   United Kingdom;
   University Hospital Gent
      2006   -   EUCTR2006-003836-31-BE   Belgium;
   University Hospital, Ghent
      2009   Phase 2   NCT00936546   Belgium;
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan;
   Yoshizaki Ayumi
      2012   Phase 2   JPRN-jRCTs031180373   Japan;
Ro 47-0203   
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom;
Ro 487-7533/F10-04   
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Ro47-0203 / ACT-050088   
   Actelion Pharmaceuticals Japan Ltd.
      2013   Phase 3   JPRN-JapicCTI-132176   -
RoActemra   
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-000424-28-IE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-000424-28-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-NL   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-LT   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-HR   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000424-28-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Rosemary   
   ARCIM Institute Academic Research in Complementary and Integrative Medicine
      2015   -   NCT03531216   Germany;
Rosuvastatin   
   Faculty of Medicine, University of Alexandria
      2008   Phase 3   NCT00984932   Egypt;
SAR100842   
   SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT
      2013   -   EUCTR2012-001369-34-IT   Canada;Germany;Italy;Switzerland;United Kingdom;United States;
   Sanofi
      2013   Phase 2   NCT01651143   France;Germany;Italy;Switzerland;United Kingdom;United States;
   Sanofi-aventis recherche & développement
      2012   Phase 2   EUCTR2012-001369-34-GB   Canada;Germany;Italy;Switzerland;United Kingdom;United States;
      2012   -   EUCTR2012-001369-34-DE   Canada;Germany;Switzerland;United Kingdom;United States;
SAR156597   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2016   Phase 2   EUCTR2016-001028-80-IT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   Sanofi
      2016   Phase 2   NCT02921971   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   sanofi-aventis recherche & développement
      2016   Phase 2   EUCTR2016-001028-80-EE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001028-80-DE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001028-80-BE   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-001028-80-AT   Argentina;Austria;Belgium;Estonia;France;Germany;Italy;Mexico;Poland;Romania;Russian Federation;United Kingdom;United States;
SAR231893   
   University of Cologne
      2019   Phase 2   EUCTR2019-002036-90-DE   Germany;
SINVACOR*28CPR RIV   
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-006035-32-IT   Italy;
SODIUM NITROPRUSSIDE   
   Salford Royal Hospitals Trust
      2007   Phase 2   EUCTR2004-002799-41-GB   United Kingdom;
SODIUM THIOSULFATE PENTAHYDRATE   
   CHU de LIMOGES
      2019   Phase 2   EUCTR2018-001978-22-FR   France;
STI571   
   Novartis Pharma Services AG
      2008   -   EUCTR2007-004669-17-GB   Italy;United Kingdom;
      2008   -   EUCTR2007-004669-17-DE   Germany;Italy;United Kingdom;
   Novartis Pharmaceuticals
      2008   Phase 2   NCT00613171   Germany;Italy;Switzerland;United Kingdom;United States;
STS   
   University Hospital, Limoges
      2020   Phase 2   NCT03582800   France;
Saccharomyces Boulardii Oral Tablet   
   Coordinación de Investigación en Salud, Mexico
      2015   Phase 4   NCT03692299   Mexico;
Selexipag   
   Actelion
      2014   Phase 2   NCT02260557   France;Germany;United Kingdom;
Self bone marrow transplant   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
Serial night time position splint   
   Federal University of São Paulo
      2010   Phase 3   NCT01586663   Brazil;
Sildenafil   
   Johns Hopkins University
      2021   Phase 2   NCT04797286   United States;
   University Hospital, Lille
      2010   Phase 3   NCT01295736   France;
Sildenafil 20mg and Bosentan   
   Postgraduate Institute of Medical Education and Research
      2016   Phase 4   NCT03053739   India;
Sildenafil citrate   
   Federal University of São Paulo
      2011   Phase 3   NCT01347008   Brazil;
Sildenafil therapy   
   Charite University, Berlin, Germany
      2004   Phase 2   NCT00624273   Germany;
Simvastatin   
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-006035-32-IT   Italy;
Sirolimus   
   Peking University People's Hospital
      2018   Phase 2   NCT03365869   -
   The First Affiliated Hospital of China Medical University
      2020   Phase 0   ChiCTR2000030370   China;
Sodium chloride   
   Radboud University
      2017   Early Phase 1   NCT03059979   Netherlands;
Sodium fluoride 18F   
   University Medial Center Groningen
      2018   Phase 4   EUCTR2018-001719-65-NL   Netherlands;
Solid state catheter   
   University of Utah
      2004   Phase 4   NCT00204763   United States;
Solu-Medrone   
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Solu-medrone   
   Newcastle upon Tyne NHS Foundation Trust
      2008   Phase 4   EUCTR2008-000224-27-GB   United Kingdom;
Soluble Ve cadherin   
   University Hospital, Grenoble
      2014   -   NCT02212249   France;
Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)   
   University Hospital, Strasbourg, France
      2021   -   NCT04627857   France;
Standard of care   
   Northwestern University
      2005   Phase 2   NCT00278525   United States;
Stem cell transplantation   
   Northwestern University
      2005   Phase 2   NCT00278525   United States;
Sterile saline solution   
   Johns Hopkins University
      2015   Phase 3   NCT02165111   United States;
Steroids   
   RenJi Hospital
      2017   Phase 2/Phase 3   NCT03068234   China;
Stromal Vascular fraction   
   Assistance Publique Hopitaux De Marseille
      2017   Phase 2   NCT02866552   France;
      2015   Phase 2   NCT02558543   France;
Study of the gene expression profile   
   Assistance Publique Hopitaux De Marseille
      2018   -   NCT03629002   France;
TERGURIDE HYDROGENMALEATE   
   MEDAC GMBH
      2016   Phase 3   EUCTR2015-002586-39-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
   medac GmbH
      2017   Phase 3   EUCTR2015-002586-39-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-PT   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-GB   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-FR   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002586-39-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Switzerland;United Kingdom;United States;
TRACLEER*125MG 56CPR RIV.   
   ACTELION PHARMACEUTICALS ITALIA
      2004   -   EUCTR2004-000631-28-IT   Italy;
TRACLEER*56CPR RIV   
   ACTELION PHARMACEUTICALS ITALIA
      2005   -   EUCTR2004-000632-82-IT   Italy;
Tacrolimus   
   Fred Hutchinson Cancer Research Center
      2006   Phase 1/Phase 2   NCT00622895   United States;
   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
      2010   Phase 2   NCT01047072   United States;
   Medical College of Wisconsin
      2016   Phase 1   NCT02680717   -
   The First Affiliated Hospital of Guangzhou University of Chinese Medicine
      2021   Phase 0   ChiCTR2100042327   China;
Tadalafil   
   Sanjay Gandhi Postgraduate Institute of Medical Sciences
      2012   Phase 3   NCT01553981   India;
      2009   Phase 3   NCT01117298   India;
      2007   Phase 3   NCT00626665   -
Tadalafil and ambrisentan upfront combination therapy   
   Johns Hopkins University
      2010   Phase 4   NCT01042158   United States;
Temanogrel   
   Arena Pharmaceuticals
      2021   Phase 2   NCT04915950   United Kingdom;United States;
Terguride   
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany;
Thalidomide   
   New York University School of Medicine
      2000   Phase 1   NCT00418132   United States;
The ozone generator device (Human Pro medic, German)   
   Assiut University
      2016   -   NCT02733978   -
Thiotepa   
   Paul Szabolcs
      2018   Phase 2   NCT03630211   United States;
Thymoglobulin   
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2002   Phase 1   NCT00040651   United States;
Thymoglobuline   
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2006-004598-83-GB   United Kingdom;
Tocilizumab   
   CHUGAI PHARMACEUTICAL CO., LTD
      2017   Phase 3   JPRN-JapicCTI-173760   Japan;
   Chugai Pharmaceutical Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-152963   Japan, North America, Europe, 25 countries including Japan, US, UK, Germany etc.;
   Hoffmann-La Roche
      2015   Phase 3   NCT02453256   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Greece;Hungary;Italy;Japan;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;South Africa;Spain;Switzerland;United Kingdom;United States;
   Kanazawa University Hospital
      2016   -   JPRN-UMIN000022624   Japan;
   Kanazawa University Hospital, Department of dermatology
      2015   -   JPRN-UMIN000020389   Japan;
   Osaka University
      2014   -   JPRN-UMIN000015495   Japan;
   Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine
      2011   Phase 2   JPRN-UMIN000005550   Japan;
   The University of Tokyo
      2013   -   JPRN-UMIN000012214   Japan;
   Yoshizaki Ayumi
      2013   Phase 2   JPRN-jRCTs031180370   Japan;
Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS)   
   F. Hoffmann-La Roche Ltd.
      2012   Phase 2;Phase 3   EUCTR2011-001460-22-GB   Canada;France;Germany;United Kingdom;United States;
      2011   -   EUCTR2011-001460-22-DE   Canada;France;Germany;United Kingdom;United States;
Tocilizumab [RoActemra/Actemra]   
   Hoffmann-La Roche
      2012   Phase 3   NCT01532869   Canada;France;Germany;United Kingdom;United States;
Tofacitinib   
   University of Michigan
      2017   Phase 1/Phase 2   NCT03274076   United States;
Topical AmphiMatrix   
   MediQuest Therapeutics
      2007   Phase 3   NCT00577304   United States;
Topical AmphiMatrix with nitroglycerin (MQX-503)   
   MediQuest Therapeutics
      2006   Phase 3   NCT00419419   Sweden;United Kingdom;United States;
Topical calcipotriene ointment   
   Northwestern University
      2015   -   NCT02411643   United States;
Topical organogel with nitroglycerin   
   MediQuest Therapeutics
      2004   Phase 2/Phase 3   NCT00253331   United States;
Total Body Irradiation   
   Baylor College of Medicine
      1999   Phase 1   NCT00058578   United States;
Total-Body Irradiation   
   City of Hope Medical Center
      2022   Early Phase 1   NCT04380831   United States;
Tracleer   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   Phase 3   EUCTR2010-021452-26-FR   France;
   Actelion Pharmaceuticals Ltd.
      2004   Phase 3   EUCTR2004-000632-82-GB   Italy;United Kingdom;
   Actelion Pharmaceuticals Nederland bv
      2012   -   EUCTR2011-005303-32-NL   Netherlands;
   University College London
      2005   Phase 2   EUCTR2005-000701-61-GB   United Kingdom;
   University Medical Center Groningen (UMCG)
      2016   -   EUCTR2014-002796-28-NL   Netherlands;
Transdihydrolisuride   
   University Hospital Zurich
      2010   -   EUCTR2009-017869-27-DE   Germany;
Treprostinil diethanolamine   
   United Therapeutics
      2009   Phase 2   NCT00848107   Canada;United Kingdom;United States;
      2009   Phase 2   NCT00775463   Canada;United Kingdom;United States;
      2008   Phase 1   NCT00848939   United States;
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
      2009   -   EUCTR2008-005018-39-GB   United Kingdom;
Trimebutine   
   Third Department of Internal Medicine (Department of Rheumatology) Shimane University Faculty of Medicine
      2017   Phase 3   JPRN-UMIN000026859   Japan;
UCMSC   
   Marie Hudson, MD
      2022   Phase 1/Phase 2   NCT04356287   -
UT-15 SR   
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
UT-15C SR   
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
      2009   -   EUCTR2008-005018-39-GB   United Kingdom;
UT-15C-SR   
   United Therapeutics Corporation
      2009   -   EUCTR2008-006978-15-GB   Canada;United Kingdom;United States;
      2009   -   EUCTR2008-005018-39-GB   United Kingdom;
Ultraviolet A1 phototherapy (UVA1)   
   Cairo University
      2013   -   NCT02002897   Egypt;
Urine sample   
   University Hospital, Bordeaux
      2018   -   NCT03575156   France;
VIB7734   
   Viela Bio
      2018   Phase 1   NCT03817424   Poland;Spain;United States;
VIP   
   MONDOGEN AG
      2008   -   EUCTR2007-003621-24-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   MondoGEN AG
      2009   -   EUCTR2007-003621-24-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-003621-24-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-003621-24-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Vaseline   
   Mohammad Ali Nazarinia
      2016   Phase 2   NCT02801305   Iran, Islamic Republic of;
Veledimex   
   Castle Creek Biosciences, LLC.
      2019   Phase 1/Phase 2   NCT03740724   United States;
Vitamin D3   
   Coordinación de Investigación en Salud, Mexico
      2017   -   NCT04822038   Mexico;
Vivomixx probiotics   
   Singapore General Hospital
      2013   Phase 2   NCT01804959   Singapore;
Volibris   
   Thoraxklinik-Heidelberg gGmbH
      2014   Phase 2   EUCTR2014-001882-28-DE   Germany;
Yellow Fever vaccine (17D)   
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;
ZD4054   
   University College London
      2014   Phase 2   EUCTR2013-003200-39-GB   United Kingdom;
Zibotentan   
   University College London
      2014   Phase 2   EUCTR2013-003200-39-GB   United Kingdom;
   University College, London
      2014   Phase 2   NCT02047708   United Kingdom;
Ziritaxestat   
   Galapagos NV
      2019   Phase 2   EUCTR2019-001279-34-GB   Belgium;Germany;Italy;Spain;United Kingdom;United States;